Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > ULURU Inc. Announces the Appointment of Ronald A. Ahrens to the Board of Directors

Abstract:
ULURU Inc. (Amex: ULU) announced today that Ronald A. Ahrens has been appointed to serve on the
Company's Board of Directors.

ULURU Inc. Announces the Appointment of Ronald A. Ahrens to the Board of Directors

ADDISON, TX | Posted on June 23rd, 2008

Mr. Ahrens has been an advisor to Merck & Company, Inc. since 1995, when
he retired as President of Merck Consumer Healthcare Group Worldwide. He had
previously served as Executive Vice President of Merck Consumer Healthcare
Group International. From 1985 to 1990 Mr. Ahrens was Consumer Group
President, North America of Bristol-Myers Squibb and previously was President
of Bristol Myers Products Division. Prior to 1985, he held senior management
and sales and marketing positions with Richardson Vicks, Bristol-Myers Squibb
and Procter and Gamble.

"I am extremely impressed with ULURU's range of innovative products and
look forward to providing insight and guidance as they commercialize their
numerous product opportunities. The company is now at a point where I believe
my experience can assist the company to enhance share holder value," said Mr.
Ahrens.

Commenting on the appointment, Kerry P. Gray, President and Chief
Executive Officer of ULURU, stated, "We are excited to have Ron join our
Board, as he has vast experience successfully commercializing numerous
products, and has been involved with a wound care company. His extensive
industry experience and contacts will be extremely helpful as we commercialize
products both internally and with strategic partners."

####

About ULURU Inc.
ULURU Inc. is a specialty pharmaceutical company focused on the
development of a portfolio of wound management, plastic surgery and oral care
products to provide patients and consumers improved clinical outcomes through
controlled delivery utilizing its innovative transmucosal delivery system and
Hydrogel Nanoparticle Aggregate technology.

This press release contains certain statements that are forward-looking
within the meaning of Section 27a of the Securities Act of 1933, as amended,
including but not limited to statements made relating to the value of our
products in the marketplace, our ability to develop and market our
technologies and commercialization of products in the marketplace. These
statements are subject to numerous risks and uncertainties, including but not
limited to the risk factors detailed in the Company's Annual Report on Form
10-KSB for the year ended December 31, 2007, Quarterly Report on Form 10-Q for
the quarter ended March 31, 2008 and other reports filed by us with the
Securities and Exchange Commission.

For more information, please click here

Contacts:
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

New Method Uses DNA, Nanoparticles and Top-Down Lithography to Make Optically Active Structures: Technique could lead to new classes of materials that can bend light, such as for those used in cloaking devices January 18th, 2018

Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock January 18th, 2018

Leti to Demo New Curving Technology at Photonics West that Improves Performance of Optical Components January 18th, 2018

Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock January 17th, 2018

Nanomedicine

Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock January 18th, 2018

Leti to Demo New Curving Technology at Photonics West that Improves Performance of Optical Components January 18th, 2018

Ultra-thin optical fibers offer new way to 3-D print microstructures: Novel approach lays groundwork for using 3-D printing to repair tissue in the body January 17th, 2018

Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock January 17th, 2018

Announcements

New Method Uses DNA, Nanoparticles and Top-Down Lithography to Make Optically Active Structures: Technique could lead to new classes of materials that can bend light, such as for those used in cloaking devices January 18th, 2018

Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock January 18th, 2018

Leti to Demo New Curving Technology at Photonics West that Improves Performance of Optical Components January 18th, 2018

Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock January 17th, 2018

Appointments/Promotions/New hires/Resignations/Deaths

Ocean Optics Grows Sales Organization with Executive Appointments: Henry Langston promoted, Christine Stannard joins spectral sensing product developer December 23rd, 2017

Emmanuel Sabonnadiere is Letiís New CEO November 28th, 2017

Nanometrics Board of Directors Names Pierre-Yves Lesaicherre President and CEO November 14th, 2017

180 Degree Capital Corp. Appoints Investment Banking Veteran Parker Weil to Its Board of Directors August 2nd, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project